Amendment: SEC Form SCHEDULE 13G/A filed by Corvus Pharmaceuticals Inc.
$CRVS
Biotechnology: Pharmaceutical Preparations
Health Care
|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13G
|
UNDER THE SECURITIES EXCHANGE ACT OF 1934
|
(Amendment No. 10)
|
Corvus Pharmaceuticals, Inc. (Name of Issuer) |
Common Stock, $0.0001 par value per share (Title of Class of Securities) |
221015100 (CUSIP Number) |
12/31/2025 (Date of Event Which Requires Filing of this Statement) |
| Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
 Rule 13d-1(b)
|
| Rule 13d-1(c)
|
 Rule 13d-1(d)
|
SCHEDULE 13G
|
| CUSIP No. | 221015100 |
| 1 | Names of Reporting Persons
Richard A. Miller | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
UNITED STATES
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
6,085,922.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
7.8 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
IN |
SCHEDULE 13G
|
| CUSIP No. | 221015100 |
| 1 | Names of Reporting Persons
Richard A. Miller and Sandra J. Horning, Trustees of the Miller-Horning Family Trust u/a/d January 25, 1985 | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
CALIFORNIA
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
1,188,103.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
1.6 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
OO |
SCHEDULE 13G
|
| CUSIP No. | 221015100 |
| 1 | Names of Reporting Persons
Sandra J. Horning | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
UNITED STATES
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
1,188,103.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
1.6 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
IN |
SCHEDULE 13G
|
| Item 1. | ||
| (a) | Name of issuer:
Corvus Pharmaceuticals, Inc. | |
| (b) | Address of issuer's principal executive offices:
901 Gateway Boulevard, Third Floor, South San Francisco, CA 94080 | |
| Item 2. | ||
| (a) | Name of person filing:
Richard A. Miller ("Dr. Miller")
Richard A. Miller and Sandra J. Horning, Trustees of the Miller-Horning Family
Trust u/a/d January 25, 1985 (the "Miller-Horning Trust")
Sandra J. Horning ("Dr. Horning," and collectively with Dr. Miller and the Miller-Horning Trust, the "Reporting Persons") | |
| (b) | Address or principal business office or, if none, residence:
c/o Corvus Pharmaceuticals, Inc., 901 Gateway Boulevard, Third Floor, South San Francisco, CA 94080 | |
| (c) | Citizenship:
Dr. Miller is a U.S. citizen. The Miller-Horning Trust is organized under the laws of the State of California. Dr. Horning is a U.S. citizen. | |
| (d) | Title of class of securities:
Common Stock, $0.0001 par value per share | |
| (e) | CUSIP No.:
221015100 | |
| Item 3. | If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: | |
| (a) | Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
| |
| (b) | Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
| |
| (c) | Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
| |
| (d) | Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
| |
| (e) | An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
| |
| (f) | An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
| |
| (g) | A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
| |
| (h) | A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
| |
| (i) | A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
| |
| (j) | A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution: | |
| (k) | Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
| |
| Item 4. | Ownership | |
| (a) | Amount beneficially owned:
The ownership information presented below represents beneficial ownership of Common Stock of the Issuer as of December 31, 2025, based upon 74,681,872 shares of Common Stock outstanding as of November 4, 2025, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 4, 2025. All percentages assume the exercise of stock options held directly by each of the Reporting Persons, as applicable.
Dr. Miller is the beneficial owner of 6,085,922 shares of Common Stock, which consists of (i) 1,136,707 shares of Common Stock held directly by Dr. Miller, (ii) 1,188,103 shares of Common Stock directly held by the Miller-Horning Trust, over which Dr. Miller and Dr. Horning share voting, investment and dispositive power, and (iii) 3,761,112 shares of Common Stock underlying stock options that are vested or will vest within 60 days of December 31, 2025.
Each of the Miller-Horning Trust and Dr. Horning is the beneficial owner of 1,188,103 shares of Common Stock. | |
| (b) | Percent of class:
Dr. Miller - 7.8%
Miller-Horning Trust - 1.6%
Dr. Horning - 1.6% | |
| (c) | Number of shares as to which the person has:
| |
| (i) Sole power to vote or to direct the vote:
Dr. Miller - 4,897,819
Miller-Horning Trust - 0
Dr. Horning - 0 | ||
| (ii) Shared power to vote or to direct the vote:
Dr. Miller - 1,188,103
Miller-Horning Trust - 1,188,103
Dr. Horning - 1,188,103 | ||
| (iii) Sole power to dispose or to direct the disposition of:
Dr. Miller - 4,897,819
Miller-Horning Trust - 0
Dr. Horning - 0 | ||
| (iv) Shared power to dispose or to direct the disposition of:
Dr. Miller - 1,188,103
Miller-Horning Trust - 1,188,103
Dr. Horning - 1,188,103 | ||
| Item 5. | Ownership of 5 Percent or Less of a Class. | |
Not Applicable
| ||
| Item 6. | Ownership of more than 5 Percent on Behalf of Another Person. | |
Not Applicable
| ||
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. | |
Not Applicable
| ||
| Item 8. | Identification and Classification of Members of the Group. | |
Not Applicable
| ||
| Item 9. | Notice of Dissolution of Group. | |
Not Applicable
| ||
| Item 10. | Certifications: |
Not Applicable
|
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|
|
|
|
|